Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Astellas Pharma Inc. 주요 수익원은 Pharmaceutical이며, 최신 수익 발표에서 수익은 1,912,323,000,000입니다. 지역별로는 United States이 Astellas Pharma Inc.의 주요 시장이며, 수익은 866,378,000,000입니다.
Astellas Pharma Inc.은 수익성이 있나요?
no, 최신 재무제표에 따르면 Astellas Pharma Inc.의 순손실은 $0입니다.